These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 9312835)

  • 21. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
    Ozaki K; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
    Ong G; Goh KT; Ma S; Chew SK
    J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children.
    Glikmann G; Petersen I; Mordhorst CH
    Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of MMR vaccine on mumps infection in England and Wales.
    Jones AG; White JM; Begg NT
    CDR (Lond Engl Rev); 1991 Aug; 1(9):R93-6. PubMed ID: 1669792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
    Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
    An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Incubation vaccination ("post-exposure vaccination") with MMR vaccine during a mumps epidemic? The Pediatric Vaccine Counseling Unit].
    Wiersbitzky S; Bruns R; Beyer B
    Kinderarztl Prax; 1992 Oct; 60(7):207-8. PubMed ID: 1359187
    [No Abstract]   [Full Text] [Related]  

  • 29. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 30. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
    Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phylogenetic analysis of clinical mumps virus isolates from vaccinated and non-vaccinated patients with mumps during an outbreak, Switzerland 1998-2000.
    Utz S; Richard JL; Capaul S; Matter HC; Hrisoho MG; Mühlemann K
    J Med Virol; 2004 May; 73(1):91-6. PubMed ID: 15042654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MMR vaccine is not linked to Crohn's disease or autism.
    Commun Dis Rep CDR Wkly; 1998 Mar; 8(13):113. PubMed ID: 9592960
    [No Abstract]   [Full Text] [Related]  

  • 37. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.